Synergic effects of the cyclin-dependent kinase (CDK) inhibitor olomoucine and androgen-antagonist bicalutamide on prostatic cancer cell lines

Neoplasma

Volumn 51, Issue 5, 2004, Pages 358-367

  Knillova J ^a   Bouchal, J ^a   Hlobilkova A ^a   Strnad, M ^a   Kolar Z ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Apoptosis; Bicalutamide; Cyclin dependent kinase; Olomoucine; Proliferation; Prostate cancer

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CYCLIN DEPENDENT KINASE INHIBITOR; OLOMOUCINE; PROTEIN P21; PROTEIN P27;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; PROSTATE CANCER;

EID: 8444220964     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. ALLEY MC, SCUDIECO DA, MONKS A, HURSEY ML, CZERWINSKI MJ et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tatrazolium assay. Cancer Res 1988; 48: 589-601.
2. BERCHEM GJ, BOSSELER M, SUGARS LY, VOELLER HJ, ZEITLIN S, GELMANN EP. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 1995; 55: 735-738.
3. BOLLAG DM, ROZYCKI MD, EDELSTEIN SJ. Gel electrophoresis under denaturing conditions. In: Protein methods (second edition), Willey-Liss, New York, Chichester, Brisbane, Toronto 1996: 107-151, 195-223.
4. BRINKMANN AO. Mechanismus of developing androgen independence. In: Belldegrun A, editor. New Perspektives in Prostate Cancer. Isis Medical Media, Oxford 1998,77-82.
5. BRUCKHEIMER EM, GJERTSEN BT, MCDONNELL TJ. Implications of cell death regulation in the pathogenesis and treatment of prostate cancer. Semin Oncol 1999; 26: 382-398.
6. CARROLL AG, VOELLER HJ, SUGARS L, GELMANN EP. p53 oncogene mutations in three human prostate cancer cell lines. Prostate 1993; 23:123-134.
7. COPTCOAT JJ. The management of advanced prostate cancer. Blackwell Science, Oxford, London, Edinburgh, Cambridge, Carlton 1996.
8. CRAFT N, SAWYERS CL. Mechanistic concepts in androgen-dependence of prostate cancer. Cancer Metastasis Rev 1999; 17: 421-427.
9. CULIG Z, HOBISCH A, HITTMAIR A, CRONAUER MV, RADMAYR C et al. Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy. Drugs Aging 1997; 10: 50-58.
10. DAHIYA R, YOON WH, BOYLE B, SCHOENBERG S, YEN TS, NARAYAN P. Biochemical, cytogenetic, and morphological characteristics of human primary and metastatic prostate cancer cell lines. Biochem Int 1992; 27: 567-577.
11. DORAI T, GOLUBOFF ET, OLSSON CA, BUTTYAN R. Development of a hammerhead ribozyme against BCL-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents. Anticancer Res 1997; 17: 3307-3312.
12. FAN S, WANG JA, YUAN RQ, MA YX, MENG Q et al. BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins. Oncogene 1998; 16: 3069-3082.
13. FELDMAN BJ, FELDMAN D. The development of androgen-independent prostate cancer. Nature Rev Cancer 2001; 1: 34-45.
14. FREDA EA. Incidence and aetiology of prostate cancer. In: Kirk D, editor. International Handbook of Prostate Cancer. Euromed Communications, Surrey 1999: 1-12.
15. GARRETT MD, FATTAEY A. CDK inhibition and cancer therapy. Curr Opin Genet Dev 1999; 9: 104-111.
16. HAJDÚCH M, HAVLÍČEK L, VESELÝ J, NOVOTNÝ R, MIHÁL V, STRNAD M. Synthetic cyclin dependent kinase inhibitors. New generation of potent anti-cancer drugs. Adv Exp Med Biol 1999; 457: 341-353.
17. HANAHAN D, WEINBERG RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
18. HAVLÍČEK L, HANUŠ J, VESELÝ J, LECLERC S, MEIJER L et al. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem 1997; 40: 408-412.
19. HOROSZEWICZ JS, LEONG SS, KAWINSKI E, KARR JP, ROSENTHAL H et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43: 1809-1818.
20. ISAACS WB, CARTER BS, EWING CM. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 1991; 51: 4716-4720.
21. JENSTER G. The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol 1999; 26: 407-421.
22. KLOCKER H, CULIG Z, HOBISCH A, CATO AC, BARTSCH G. Androgen receptor alterations in prostatic carcinoma. Prostate 1994; 25: 266-273.
23. KNOCKAERT M, GREENGARD P, MEIJER L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002; 9: 417-425.
24. KNUDSEN KE, ARDEN KC, CAVENEE WK. Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem 1998; 273: 20213-20222.
25. KOVÁŘOVÁ H, HALADA P, MAN P, DZUBAK P, HAJDUCH M. Application of proteomics in the search for novel proteins associated with the anti-cancer effect of the synthetic cyclin-dependent kinases inhibitor, bohemine. Technol Cancer Res Treat 2002; 4: 247-256.
26. LEE VH, DUNBAR BS. Sample preparation for protein electrophoresis and transfer. In: Dunbar BS, editor. Protein Blotting: A Practical Approach. Oxford University Press, Oxford, New York, Tokyo 1994: 99-101.
27. LU S, TSAI SY, TSAI MJ. Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res 1997; 57: 4511-4516.
28. MAĎAROVÁ J, LUKEŠOVÁ M, HLOBILKOVÁ A, STRNAD M, VOJTĚŠEK B et al. Synthetic inhibitors of CDKs induce different responses in androgen sensitive and androgen insensititve prostatatic cancer cell lines. J Clin Pathol: Mol Pathol 2002; 55: 227-234.
29. MAUCHER A, VON ANGERER E. Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours. J Cancer Res Clin Oncol 1993; 119: 669-674.
30. MEIJER L. Chemical inhibitors of cyclin-dependent kinases. Prog Cell Cycle Res 1995; 1: 351-363.
31. PARKIN DM, PISANI P, FERLAY J. Global cancer statistics. CA Cancer J Clin 1999; 49: 33-64.
32. PERRY JE, TINDALL DJ. Androgens regulate the expression of proliferating cell nuclear antigen posttranscriptionally in the human prostate cancer cell line, LNCaP. Cancer Res 1996; 56: 1539-1544.
33. ROKHLIN OW, BISHOP GA, HOSTAGER BS, WALDSCHMIDT TJ, SIDORENKO SP et al. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997; 57: 1758-1768.
34. ROMIJN JC, VERKOELEN CF, SCHOEDER FH. Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostaic and cytotoxic effects. Prostate 1988; 12: 99-110.
35. RUIJTER E, MONTIRONI R, VAN DE KAA C, SCHALKEN J. Molecular changes associated with prostate cancer development. Anal Quant Cytol Histol 2001; 23: 67-88.
36. SASSE J, GALLAGHER SR. Detection of proteins. In: Ausubel FM, Brent R, Kingston RE, editors. Short Protocols in Molecular Biology (second edition). Greene Publishing Associates and John Wiley, New York 1992: 10-28.
37. SHIRAHAMA T, SAKAKURA C, SWEENEY EA, OZAWA M, TAKEMOTO M et al. Sphingosine induces apoptosis in androgen-independent human prostatic carcinoma DU-145 cells by suppression of bcl-X(L) gene expression. FEBS Lett 1997; 407: 97-100.
38. STONE KR, MICKEY DD, WUNDERLI H, MICKEY GH, PAULSON DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978; 21: 274-281.
39. STRNAD M, VESELÝ J, HAJDÚCH M, HAVLÍČEK L, RYPKA M et al. Syntetic inhibitors of cyclin-dependent kinases. Zprav klin farmakol farmac 1998; 12: 10-14 (In Czech).
40. TANG DG, LI L, CHOPRA DP, PORTER AT. Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins. Cancer Res 1998; 58: 3466-3479.
41. TILLEY WD, WILSON CM, MARCELLI M, MCPHAUL MJ. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 1990; 50: 5382-5386.
42. TRAPMAN J, BRINKMANN AO. The androgen receptor in prostate cancer. Pathol Res Pract 1996; 192: 752-760.
43. TYRRELL CJ, DENIS L, NEWLING D, SOLOWAY M, CHANNER K, COCKSHOTT ID. Casodex™ 10-200 mg daily, used as monotherapy for treatment of patients with advanced prostate cancer. Eur Urol 1998; 33: 39-53.
44. VELDSCHOLTE J, BERREVOETS CA, RIS-STALPERS C, KUIPER GG, JENSTER G et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992; 41: 665-669.
45. VESELÝ J, HAVLÍČEK L, STRNAD M, BLOW JJ, DONELLA-DEANA A et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 1994; 224: 771-786.